

**i** Coronavirus: Find the latest articles and preprints[Sign in or create an account](#)[About](#)[Tools](#)[Developers](#)[Help](#)[Europe PMC plus](#)

Search worldwide, life-sciences literature

  Search[Advanced Search](#)[Coronavirus articles and preprints](#) Search examples: ["breast cancer"](#) [Smith J](#)[Recent history](#)[Saved searches](#)[Abstract](#)[Full text](#) [Citations & impact](#)[Similar Articles](#)

# [The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].

Ma WX<sup>1</sup>, Ran XW<sup>1</sup>[Author information](#) ▶

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical Science Edition, 29 Feb 2020, 51(2):146-150 Language:chi

DOI: [10.12182/20200360606](https://doi.org/10.12182/20200360606) PMID: 32220179

Review

Share this article    

## Abstract

Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients.

## Full text links

 ▼Read article at publisher's site (DOI): [10.12182/20200360606](https://doi.org/10.12182/20200360606) 

## Citations & impact

 ▶

## Similar Articles

 ▶

 Claim to ORCID  Get citation

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our [privacy notice](#) and [cookie policy](#).

I agree, dismiss this banner

[Joining Europe PMC](#)  
[Governance](#)  
[Roadmap](#)  
[Outreach](#)

[Journal list](#)  
[Grant finder](#)  
[External links service](#)  
[RSS feeds](#)  
[Annotations](#)  
[Annotations submission service](#)

[Search restrictions](#)  
[API use cases](#)  
[SOAP web service](#)  
[Annotations API](#)  
[OAI service](#)  
[Bulk downloads](#)  
[Developers Forum](#)

[Contact us](#)

[Write](#)  
[Blog](#)  
[Tech blog](#)  
[Develop](#)

Let us know how we are doing.

### Europe PMC is part of the ELIXIR infrastructure

Europe PMC is an ELIXIR Core Data Resource [Learn more >](#)

Europe PMC is a service of the [Europe PMC Funders' Group](#), in partnership with the [European Bioinformatics Institute](#); and in cooperation with the [National Center for Biotechnology Information](#) at the U.S. includes content provided to the [PMC International archive](#) by participating publishers.



[Contact us](#) | [Privacy](#) | [Terms of use](#) | [Copyright](#) | [Accessibility](#)